VRTX · News · 20260821N

Revenue Performance and Mix

VERTEX PHARMACEUTICALS INC / MA · 2026-08-21 · Importance 54 · Surprise 40 · In source text

Vertex reported quarterly revenue of $3.33 billion, up 12.5% year over year and approximately 12.5% above expectations. Cystic fibrosis treatments remained the primary revenue contributor, while CASGEVY and JOURNAVX added revenue from sickle cell disease, beta thalassemia, and acute pain markets. The product mix indicates continued diversification beyond the cystic fibrosis franchise, although cystic fibrosis remains a major concentration risk.

Key facts

• Vertex reported quarterly revenue of $3.33 billion for Q2. source
• The guidance upgrade was said to reflect growing contributions from therapies like CASGEVY and JOURNAVX for sickle cell disease, beta thalassemia, and acute pain alongside strong cystic fibrosis performance. source
• Vertex reported Q2 adjusted EPS of $4.73, missing analyst estimates by $0.01. source

Impact estimates